US Flag logoAn official website of the United States government
Individualized Cancer Therapy Study
iCat
Data Resource:  iCat
Point of Contact:  
Katherine A. Janeway, MD,  
Project

About This Dataset
The study design consisted of clinical sequencing at four academic medical centers enrolling patients between September 5, 2012, and November 19, 2013, with one year of clinical follow-up. Participants were 30 years or younger with high-risk, recurrent, or refractory extracranial solid tumors. Tumor profiling performed on archived clinically acquired specimens consisted of mutation detection by a Sequenom assay or targeted next-generation sequencing and copy number assessment by array comparative genomic hybridization. Results were reviewed by a multidisciplinary expert panel, and iCat recommendations were made if an actionable alteration was present, and an appropriate drug was available.
Core Data Elements
Number of Cases
100
Case Sex
Female (40); Male (60)
Case Age At Diagnosis
Pediatric and Young Adult (<40 years) (100)
Case Race
Not Reported (100)
Case Ethnicity
Not Reported (100)
Case Disease Diagnosis
Adrenal Cortical Carcinoma (2); Congenital Mesoblastic Nephroma (2); Ewing Sarcoma (12); Germ Cell Tumor (2); Glomus Tumor (1); Hepatoblastoma (1); Hepatocellular Carcinoma (1); Melanoma (1); Nasopharyngeal Adenocarcinoma (1); Nested Stromal Epithelial Tumor (1); Neuroblastoma (14); Nonrhabdomyosarcoma soft-tissue sarcoma (27); Osteosarcoma (11); Plexiform Schwannoma (1); Renal Cell Carcinoma (1); Renal Medullary Carcinoma (1); Rhabdoid Tumor of Liver (1); Rhabdomyosarcoma (11); Sialoblastoma (1); Wilms Tumor (8)
Case Tumor Site
Not Reported (100)
Additional Data Elements
CLINICAL TRIAL IDENTIFIER
CASE AGE AVERAGE
13.4
CASE AGE MAXIMUM
29.8
CASE AGE MINIMUM
0.8
Grant Information
P30CA013696
Cancer Center Support Grant
Published In
https://doi.org/10.1001/jamaoncol.2015.5689
Charts
Male (60); Female (40)
60Male